Document
false--12-31Q12020truefalse0000059478P21D916160000091415000002240000023700000677500000 0000059478 2020-01-01 2020-03-31 0000059478 lly:A718NotesDueJune12025Member 2020-01-01 2020-03-31 0000059478 lly:A625Notesdue2031Member 2020-01-01 2020-03-31 0000059478 lly:A1.000NotesDueJune22022Member 2020-01-01 2020-03-31 0000059478 lly:A2.125NotesDueJune32030Member 2020-01-01 2020-03-31 0000059478 us-gaap:CommonClassAMember 2020-01-01 2020-03-31 0000059478 lly:A1.625NotesDueJune22026Member 2020-01-01 2020-03-31 0000059478 lly:A6.77NotesDueJanuary12036Member 2020-01-01 2020-03-31 0000059478 lly:A1.700Notesdue2049Member 2020-01-01 2020-03-31 0000059478 2020-04-27 0000059478 2019-01-01 2019-03-31 0000059478 us-gaap:SegmentContinuingOperationsMember 2020-01-01 2020-03-31 0000059478 us-gaap:SegmentContinuingOperationsMember 2019-01-01 2019-03-31 0000059478 us-gaap:SegmentDiscontinuedOperationsMember 2020-01-01 2020-03-31 0000059478 us-gaap:SegmentDiscontinuedOperationsMember 2019-01-01 2019-03-31 0000059478 2019-12-31 0000059478 2020-03-31 0000059478 2018-06-30 0000059478 us-gaap:TreasuryStockMember 2020-01-01 2020-03-31 0000059478 us-gaap:TreasuryStockMember 2020-03-31 0000059478 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0000059478 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0000059478 us-gaap:TrustForBenefitOfEmployeesMember 2018-12-31 0000059478 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0000059478 us-gaap:TreasuryStockMember 2018-12-31 0000059478 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0000059478 us-gaap:TreasuryStockMember 2019-01-01 2019-03-31 0000059478 us-gaap:CommonStockMember 2019-03-31 0000059478 us-gaap:NoncontrollingInterestMember 2019-01-01 2019-03-31 0000059478 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0000059478 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000059478 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0000059478 us-gaap:TreasuryStockMember 2019-12-31 0000059478 us-gaap:NoncontrollingInterestMember 2018-12-31 0000059478 us-gaap:CommonStockMember 2018-12-31 0000059478 us-gaap:TrustForBenefitOfEmployeesMember 2020-03-31 0000059478 us-gaap:CommonStockMember 2020-03-31 0000059478 us-gaap:RetainedEarningsMember 2018-12-31 0000059478 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0000059478 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0000059478 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0000059478 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-03-31 0000059478 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0000059478 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000059478 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000059478 us-gaap:RetainedEarningsMember 2019-12-31 0000059478 us-gaap:CommonStockMember 2019-12-31 0000059478 us-gaap:NoncontrollingInterestMember 2019-03-31 0000059478 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000059478 us-gaap:TrustForBenefitOfEmployeesMember 2019-12-31 0000059478 us-gaap:RetainedEarningsMember 2019-03-31 0000059478 us-gaap:NoncontrollingInterestMember 2019-12-31 0000059478 us-gaap:NoncontrollingInterestMember 2020-03-31 0000059478 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0000059478 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0000059478 us-gaap:TreasuryStockMember 2019-03-31 0000059478 us-gaap:RetainedEarningsMember 2020-03-31 0000059478 us-gaap:TrustForBenefitOfEmployeesMember 2019-03-31 0000059478 2018-12-31 0000059478 2019-03-31 0000059478 country:US us-gaap:SalesReturnsAndAllowancesMember 2020-01-01 2020-03-31 0000059478 country:US us-gaap:SalesReturnsAndAllowancesMember 2019-01-01 2019-03-31 0000059478 us-gaap:RoyaltyMember 2020-01-01 2020-03-31 0000059478 us-gaap:RoyaltyMember 2019-01-01 2019-03-31 0000059478 us-gaap:ProductMember 2020-01-01 2020-03-31 0000059478 us-gaap:ProductMember 2019-01-01 2019-03-31 0000059478 lly:CollaborationandOtherRevenueMember 2020-01-01 2020-03-31 0000059478 lly:CollaborationandOtherRevenueMember 2019-01-01 2019-03-31 0000059478 country:CN 2020-01-01 2020-03-31 0000059478 country:JP 2020-01-01 2020-03-31 0000059478 lly:OtherForeignCountriesMember 2019-01-01 2019-03-31 0000059478 srt:EuropeMember 2020-01-01 2020-03-31 0000059478 country:US 2020-01-01 2020-03-31 0000059478 country:US 2019-01-01 2019-03-31 0000059478 lly:OtherForeignCountriesMember 2020-01-01 2020-03-31 0000059478 srt:EuropeMember 2019-01-01 2019-03-31 0000059478 country:CN 2019-01-01 2019-03-31 0000059478 country:JP 2019-01-01 2019-03-31 0000059478 lly:OncologyMember 2020-01-01 2020-03-31 0000059478 lly:OtherNeuroscienceMember country:US 2019-01-01 2019-03-31 0000059478 lly:ImmunologyMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0000059478 lly:TaltzMember 2019-01-01 2019-03-31 0000059478 lly:TrulicityMemberMember country:US 2019-01-01 2019-03-31 0000059478 lly:OtherNeuroscienceMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0000059478 lly:DiabetesMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0000059478 lly:ZyprexaMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0000059478 lly:CialisMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0000059478 lly:JardianceMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0000059478 lly:CyramzaMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0000059478 lly:CyramzaMember 2020-01-01 2020-03-31 0000059478 lly:OtherImmunologyMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0000059478 lly:TaltzMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0000059478 lly:HumalogMember 2020-01-01 2020-03-31 0000059478 lly:EmgalityMember 2020-01-01 2020-03-31 0000059478 lly:AlimtaMember 2019-01-01 2019-03-31 0000059478 lly:CialisMember 2020-01-01 2020-03-31 0000059478 lly:ZyprexaMember country:US 2020-01-01 2020-03-31 0000059478 lly:OtherDiabetesMember country:US 2019-01-01 2019-03-31 0000059478 lly:OtherImmunologyMember 2020-01-01 2020-03-31 0000059478 lly:NeuroscienceMember country:US 2019-01-01 2019-03-31 0000059478 lly:AlimtaMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0000059478 lly:VerzenioMember 2020-01-01 2020-03-31 0000059478 lly:EmgalityMember 2019-01-01 2019-03-31 0000059478 lly:ForteoMember country:US 2020-01-01 2020-03-31 0000059478 lly:DiabetesMember country:US 2019-01-01 2019-03-31 0000059478 lly:BasaglarMember 2020-01-01 2020-03-31 0000059478 lly:TrulicityMemberMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0000059478 lly:HumalogMember country:US 2019-01-01 2019-03-31 0000059478 lly:OtherProductMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0000059478 lly:CymbaltaMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0000059478 lly:HumulinMember country:US 2020-01-01 2020-03-31 0000059478 lly:BasaglarMember country:US 2019-01-01 2019-03-31 0000059478 lly:HumalogMember country:US 2020-01-01 2020-03-31 0000059478 lly:CialisMember 2019-01-01 2019-03-31 0000059478 lly:OtherOncologyMember 2019-01-01 2019-03-31 0000059478 lly:VerzenioMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0000059478 lly:JardianceMember 2020-01-01 2020-03-31 0000059478 lly:NeuroscienceMember 2019-01-01 2019-03-31 0000059478 lly:CymbaltaMember 2019-01-01 2019-03-31 0000059478 lly:AlimtaMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0000059478 lly:EmgalityMember country:US 2019-01-01 2019-03-31 0000059478 lly:CialisMember country:US 2020-01-01 2020-03-31 0000059478 lly:ErbituxMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0000059478 lly:OtherProductMember 2019-01-01 2019-03-31 0000059478 lly:OtherProductTotalMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0000059478 lly:ErbituxMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0000059478 lly:OlumiantMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0000059478 lly:OtherOncologyMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0000059478 lly:TrulicityMemberMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0000059478 lly:OtherDiabetesMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0000059478 lly:OtherDiabetesMember country:US 2020-01-01 2020-03-31 0000059478 lly:OtherImmunologyMember country:US 2020-01-01 2020-03-31 0000059478 lly:ZyprexaMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0000059478 lly:ForteoMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0000059478 lly:OlumiantMember country:US 2019-01-01 2019-03-31 0000059478 lly:CymbaltaMember country:US 2020-01-01 2020-03-31 0000059478 lly:EmgalityMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0000059478 lly:OtherProductMember 2020-01-01 2020-03-31 0000059478 lly:OtherNeuroscienceMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0000059478 lly:NeuroscienceMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0000059478 lly:OncologyMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0000059478 lly:ImmunologyMember country:US 2020-01-01 2020-03-31 0000059478 lly:OncologyMember country:US 2020-01-01 2020-03-31 0000059478 lly:OtherDiabetesMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0000059478 lly:VerzenioMember country:US 2019-01-01 2019-03-31 0000059478 lly:HumulinMember country:US 2019-01-01 2019-03-31 0000059478 lly:CyramzaMember country:US 2020-01-01 2020-03-31 0000059478 lly:JardianceMember country:US 2019-01-01 2019-03-31 0000059478 lly:DiabetesMember country:US 2020-01-01 2020-03-31 0000059478 lly:TaltzMember 2020-01-01 2020-03-31 0000059478 lly:OtherProductMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0000059478 lly:OtherOncologyMember 2020-01-01 2020-03-31 0000059478 lly:HumalogMember 2019-01-01 2019-03-31 0000059478 lly:OtherProductMember country:US 2020-01-01 2020-03-31 0000059478 lly:TaltzMember country:US 2019-01-01 2019-03-31 0000059478 lly:TrajentaBIMember 2019-01-01 2019-03-31 0000059478 lly:TrulicityMemberMember 2019-01-01 2019-03-31 0000059478 lly:ZyprexaMember 2019-01-01 2019-03-31 0000059478 lly:TaltzMember country:US 2020-01-01 2020-03-31 0000059478 lly:TrajentaBIMember country:US 2019-01-01 2019-03-31 0000059478 lly:HumalogMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0000059478 lly:OncologyMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0000059478 lly:OtherOncologyMember country:US 2019-01-01 2019-03-31 0000059478 lly:OtherProductTotalMember 2019-01-01 2019-03-31 0000059478 lly:TrulicityMemberMember 2020-01-01 2020-03-31 0000059478 lly:CymbaltaMember country:US 2019-01-01 2019-03-31 0000059478 lly:OncologyMember country:US 2019-01-01 2019-03-31 0000059478 lly:AlimtaMember 2020-01-01 2020-03-31 0000059478 lly:TrajentaBIMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0000059478 lly:OtherDiabetesMember 2020-01-01 2020-03-31 0000059478 lly:ZyprexaMember 2020-01-01 2020-03-31 0000059478 lly:ImmunologyMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0000059478 lly:OtherOncologyMember country:US 2020-01-01 2020-03-31 0000059478 lly:ImmunologyMember 2020-01-01 2020-03-31 0000059478 lly:TrajentaBIMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0000059478 lly:OtherImmunologyMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0000059478 lly:OtherImmunologyMember country:US 2019-01-01 2019-03-31 0000059478 lly:VerzenioMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0000059478 lly:NeuroscienceMember country:US 2020-01-01 2020-03-31 0000059478 lly:HumulinMember 2019-01-01 2019-03-31 0000059478 lly:OtherOncologyMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0000059478 lly:NeuroscienceMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0000059478 lly:OtherNeuroscienceMember country:US 2020-01-01 2020-03-31 0000059478 lly:ForteoMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0000059478 lly:ImmunologyMember 2019-01-01 2019-03-31 0000059478 lly:CymbaltaMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0000059478 lly:BasaglarMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0000059478 lly:OlumiantMember 2019-01-01 2019-03-31 0000059478 lly:BasaglarMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0000059478 lly:CyramzaMember 2019-01-01 2019-03-31 0000059478 lly:ErbituxMember country:US 2020-01-01 2020-03-31 0000059478 lly:TaltzMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0000059478 lly:OncologyMember 2019-01-01 2019-03-31 0000059478 lly:AlimtaMember country:US 2019-01-01 2019-03-31 0000059478 lly:DiabetesMember 2020-01-01 2020-03-31 0000059478 us-gaap:NonUsMember 2020-01-01 2020-03-31 0000059478 lly:EmgalityMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0000059478 lly:OtherProductTotalMember country:US 2019-01-01 2019-03-31 0000059478 lly:CyramzaMember country:US 2019-01-01 2019-03-31 0000059478 lly:CialisMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0000059478 lly:AlimtaMember country:US 2020-01-01 2020-03-31 0000059478 lly:HumalogMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0000059478 lly:JardianceMember 2019-01-01 2019-03-31 0000059478 lly:TrajentaBIMember country:US 2020-01-01 2020-03-31 0000059478 lly:OtherDiabetesMember 2019-01-01 2019-03-31 0000059478 lly:TrajentaBIMember 2020-01-01 2020-03-31 0000059478 us-gaap:NonUsMember 2019-01-01 2019-03-31 0000059478 lly:BasaglarMember country:US 2020-01-01 2020-03-31 0000059478 lly:OtherNeuroscienceMember 2020-01-01 2020-03-31 0000059478 lly:ForteoMember 2019-01-01 2019-03-31 0000059478 lly:BasaglarMember 2019-01-01 2019-03-31 0000059478 lly:OtherProductTotalMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0000059478 lly:ErbituxMember 2020-01-01 2020-03-31 0000059478 lly:EmgalityMember country:US 2020-01-01 2020-03-31 0000059478 lly:ForteoMember country:US 2019-01-01 2019-03-31 0000059478 lly:TrulicityMemberMember country:US 2020-01-01 2020-03-31 0000059478 lly:ErbituxMember 2019-01-01 2019-03-31 0000059478 lly:VerzenioMember 2019-01-01 2019-03-31 0000059478 lly:JardianceMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0000059478 lly:OlumiantMember 2020-01-01 2020-03-31 0000059478 lly:CyramzaMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0000059478 lly:HumulinMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0000059478 lly:DiabetesMember 2019-01-01 2019-03-31 0000059478 lly:OtherProductMember country:US 2019-01-01 2019-03-31 0000059478 lly:HumulinMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0000059478 lly:ZyprexaMember country:US 2019-01-01 2019-03-31 0000059478 lly:VerzenioMember country:US 2020-01-01 2020-03-31 0000059478 lly:HumulinMember 2020-01-01 2020-03-31 0000059478 lly:DiabetesMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0000059478 lly:CialisMember country:US 2019-01-01 2019-03-31 0000059478 lly:OtherProductTotalMember country:US 2020-01-01 2020-03-31 0000059478 lly:NeuroscienceMember 2020-01-01 2020-03-31 0000059478 lly:ErbituxMember country:US 2019-01-01 2019-03-31 0000059478 lly:OtherImmunologyMember 2019-01-01 2019-03-31 0000059478 lly:OlumiantMember country:US 2020-01-01 2020-03-31 0000059478 lly:OlumiantMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0000059478 lly:OtherNeuroscienceMember 2019-01-01 2019-03-31 0000059478 lly:ForteoMember 2020-01-01 2020-03-31 0000059478 lly:ImmunologyMember country:US 2019-01-01 2019-03-31 0000059478 lly:OtherProductTotalMember 2020-01-01 2020-03-31 0000059478 lly:JardianceMember country:US 2020-01-01 2020-03-31 0000059478 lly:CymbaltaMember 2020-01-01 2020-03-31 0000059478 lly:ACImmuneSAMember 2019-01-01 2019-01-31 0000059478 lly:ImmuNextInc.Member 2019-03-01 2019-03-31 0000059478 lly:SitryxTherapeuticsLimitedMember 2020-01-01 2020-03-31 0000059478 lly:LoxoOncologyInc.Member 2019-02-15 0000059478 lly:SelpercatinibLOXO292Member lly:LoxoOncologyInc.Member 2019-02-15 0000059478 lly:LoxoOncologyInc.Member 2019-02-01 2019-02-28 0000059478 lly:LoxoOncologyInc.Member us-gaap:ContractBasedIntangibleAssetsMember 2019-02-15 2019-02-15 0000059478 lly:ACImmuneSAMember 2019-09-01 2019-09-30 0000059478 lly:DermiraInc.Member 2020-03-01 2020-03-31 0000059478 lly:DermiraInc.Member 2020-02-29 0000059478 lly:AbCelleraBiologicsInc.Member 2020-03-31 0000059478 lly:DermiraInc.Member 2020-02-20 2020-02-20 0000059478 lly:LebrikizumabMember 2020-03-31 0000059478 lly:TanezumabMember lly:MilestonePaymentsSalesBasedMember 2020-01-01 2020-03-31 0000059478 lly:RocheMember lly:LebrikizumabMember lly:MilestonePaymentsSalesBasedMember 2020-01-01 2020-03-31 0000059478 lly:OlumiantMember lly:MilestonePaymentsSalesBasedMember 2020-01-01 2020-03-31 0000059478 lly:RocheMember lly:LebrikizumabMember lly:MilestonePaymentsDevelopmentAndRegulatoryMember 2020-01-01 2020-03-31 0000059478 lly:OlumiantMember us-gaap:RoyaltyAgreementTermsMember 2020-01-01 2020-03-31 0000059478 lly:TanezumabMember lly:MilestonePaymentsDevelopmentAndRegulatoryMember 2020-01-01 2020-03-31 0000059478 lly:LebrikizumabMember lly:MilestonePaymentsDevelopmentAndRegulatoryMember 2020-01-01 2020-03-31 0000059478 lly:LebrikizumabMember lly:MilestonePaymentsSalesBasedMember 2020-01-01 2020-03-31 0000059478 lly:OlumiantMember lly:MilestonePaymentsDevelopmentAndRegulatoryMember 2020-01-01 2020-03-31 0000059478 lly:OlumiantMember lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember 2020-01-01 2020-03-31 0000059478 lly:TrajentaBIMember lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember 2020-01-01 2020-03-31 0000059478 lly:JardianceMember lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember 2020-01-01 2020-03-31 0000059478 lly:BasaglarMember lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember 2020-01-01 2020-03-31 0000059478 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember lly:ElancoAnimalHealthIncorporatedMember 2019-03-11 2019-03-11 0000059478 lly:EliLillyAndCompanyMember us-gaap:DiscontinuedOperationsDisposedOfBySaleMember lly:ElancoAnimalHealthIncorporatedMember 2019-03-11 0000059478 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember lly:ElancoAnimalHealthIncorporatedMember 2020-01-01 2020-03-31 0000059478 lly:LoxoOncologyInc.Member 2020-01-01 2020-03-31 0000059478 us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-01 2020-03-31 0000059478 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2020-01-01 2020-03-31 0000059478 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-01 2020-03-31 0000059478 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-01-01 2019-03-31 0000059478 lly:HedgedFixedRateDebtMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-01 2020-03-31 0000059478 us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-01-01 2019-03-31 0000059478 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2019-01-01 2019-03-31 0000059478 lly:HedgedFixedRateDebtMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-01-01 2019-03-31 0000059478 lly:SwapU.S.DollarsToEuroMember 2020-03-31 0000059478 lly:BuyEuroSellUsDollarMember 2020-03-31 0000059478 lly:BuyUsDollarSellEuroMember 2020-03-31 0000059478 lly:BuyBritishPoundandSellUSDollarsMember 2020-03-31 0000059478 lly:SwapSwissFrancsToU.S.DollarsMember 2020-03-31 0000059478 lly:BuyUSdollarSellJapaneseYenMember 2020-03-31 0000059478 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000059478 lly:SwapU.S.DollarsToBritishPoundsMember 2020-03-31 0000059478 lly:ForeignCurrencyDenominatedDebtMember 2020-03-31 0000059478 lly:SeniorNotesDueApril2050Member us-gaap:SeniorNotesMember us-gaap:SubsequentEventMember 2020-04-30 0000059478 lly:ForeignCurrencyDenominatedDebtMember 2019-12-31 0000059478 lly:HedgedFixedRateDebtMember 2019-01-01 2019-03-31 0000059478 us-gaap:CrossCurrencyInterestRateContractMember 2020-01-01 2020-03-31 0000059478 us-gaap:InterestRateSwapMember 2019-01-01 2019-03-31 0000059478 lly:HedgedFixedRateDebtMember 2020-01-01 2020-03-31 0000059478 us-gaap:InterestRateSwapMember 2020-01-01 2020-03-31 0000059478 us-gaap:CrossCurrencyInterestRateContractMember 2019-01-01 2019-03-31 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-03-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-12-31 0000059478 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-12-31 0000059478 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-03-31 0000059478 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-12-31 0000059478 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-03-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-03-31 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-12-31 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-12-31 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-03-31 0000059478 us-gaap:ForeignExchangeContractMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:NondesignatedMember 2019-12-31 0000059478 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000059478 us-gaap:ForeignExchangeContractMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:NondesignatedMember 2019-12-31 0000059478 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000059478 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:NondesignatedMember 2020-03-31 0000059478 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000059478 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:NondesignatedMember 2019-12-31 0000059478 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000059478 us-gaap:InterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000059478 us-gaap:InterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000059478 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000059478 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000059478 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000059478 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000059478 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:NondesignatedMember 2020-03-31 0000059478 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000059478 us-gaap:InterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000059478 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000059478 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000059478 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000059478 us-gaap:ForeignExchangeContractMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:NondesignatedMember 2020-03-31 0000059478 us-gaap:InterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000059478 us-gaap:InterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000059478 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000059478 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000059478 us-gaap:ForeignExchangeContractMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:NondesignatedMember 2020-03-31 0000059478 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:NondesignatedMember 2019-12-31 0000059478 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000059478 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:NondesignatedMember 2019-12-31 0000059478 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000059478 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:NondesignatedMember 2020-03-31 0000059478 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000059478 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000059478 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000059478 us-gaap:InterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000059478 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000059478 us-gaap:InterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000059478 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000059478 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000059478 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000059478 us-gaap:InterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000059478 us-gaap:InterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000059478 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000059478 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000059478 us-gaap:InterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000059478 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000059478 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000059478 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000059478 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000059478 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000059478 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-03-31 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-03-31 0000059478 us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember lly:MarketableSecuritiesMember 2019-12-31 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember lly:MarketableSecuritiesMember 2019-12-31 0000059478 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:CorporateDebtSecuritiesMember 2020-03-31 0000059478 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000059478 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:OtherDebtSecuritiesMember 2020-03-31 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember lly:EquityMethodAndOtherInvestmentsMember 2020-03-31 0000059478 us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember us-gaap:OtherDebtSecuritiesMember 2019-12-31 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember lly:MarketableSecuritiesMember 2020-03-31 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:MortgageBackedSecuritiesMember 2019-12-31 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember lly:OtherEquitySecuritiesMember 2020-03-31 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:CorporateDebtSecuritiesMember 2020-03-31 0000059478 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:OtherDebtSecuritiesMember 2019-12-31 0000059478 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:AssetBackedSecuritiesMember 2019-12-31 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:AssetBackedSecuritiesMember 2019-12-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:OtherDebtSecuritiesMember 2020-03-31 0000059478 us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember lly:OtherEquitySecuritiesMember 2020-03-31 0000059478 us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember lly:OtherEquitySecuritiesMember 2019-12-31 0000059478 us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember us-gaap:MortgageBackedSecuritiesMember 2019-12-31 0000059478 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0000059478 us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:MortgageBackedSecuritiesMember 2020-03-31 0000059478 us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember us-gaap:MortgageBackedSecuritiesMember 2020-03-31 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:AssetBackedSecuritiesMember 2020-03-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember lly:MarketableSecuritiesMember 2020-03-31 0000059478 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:AssetBackedSecuritiesMember 2020-03-31 0000059478 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:AssetBackedSecuritiesMember 2020-03-31 0000059478 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember lly:OtherEquitySecuritiesMember 2020-03-31 0000059478 us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember us-gaap:AssetBackedSecuritiesMember 2020-03-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000059478 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:OtherDebtSecuritiesMember 2020-03-31 0000059478 us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-03-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:MortgageBackedSecuritiesMember 2019-12-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:CorporateDebtSecuritiesMember 2020-03-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:OtherDebtSecuritiesMember 2019-12-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-03-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember lly:OtherEquitySecuritiesMember 2020-03-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:AssetBackedSecuritiesMember 2019-12-31 0000059478 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:MortgageBackedSecuritiesMember 2019-12-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember lly:MarketableSecuritiesMember 2019-12-31 0000059478 us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember 2020-03-31 0000059478 us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember us-gaap:CorporateDebtSecuritiesMember 2020-03-31 0000059478 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember lly:OtherEquitySecuritiesMember 2020-03-31 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:MortgageBackedSecuritiesMember 2020-03-31 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:AssetBackedSecuritiesMember 2019-12-31 0000059478 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:OtherDebtSecuritiesMember 2019-12-31 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:CorporateDebtSecuritiesMember 2020-03-31 0000059478 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember lly:MarketableSecuritiesMember 2019-12-31 0000059478 us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember us-gaap:OtherDebtSecuritiesMember 2020-03-31 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:OtherDebtSecuritiesMember 2019-12-31 0000059478 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-03-31 0000059478 us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember lly:MarketableSecuritiesMember 2020-03-31 0000059478 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:AssetBackedSecuritiesMember 2019-12-31 0000059478 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember lly:MarketableSecuritiesMember 2020-03-31 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember lly:OtherEquitySecuritiesMember 2019-12-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:MortgageBackedSecuritiesMember 2020-03-31 0000059478 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:MortgageBackedSecuritiesMember 2020-03-31 0000059478 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:MortgageBackedSecuritiesMember 2019-12-31 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember lly:MarketableSecuritiesMember 2019-12-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:AssetBackedSecuritiesMember 2020-03-31 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember lly:OtherEquitySecuritiesMember 2020-03-31 0000059478 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember lly:MarketableSecuritiesMember 2019-12-31 0000059478 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0000059478 us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember lly:OtherEquitySecuritiesMember 2019-12-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:AssetBackedSecuritiesMember 2020-03-31 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember lly:MarketableSecuritiesMember 2020-03-31 0000059478 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember lly:OtherEquitySecuritiesMember 2019-12-31 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:OtherDebtSecuritiesMember 2020-03-31 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0000059478 us-gaap:CarryingReportedAmountFairValueDisclosureMember lly:EquityMethodAndOtherInvestmentsMember 2019-12-31 0000059478 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:CorporateDebtSecuritiesMember 2020-03-31 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:MortgageBackedSecuritiesMember 2019-12-31 0000059478 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember lly:MarketableSecuritiesMember 2020-03-31 0000059478 us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember 2019-12-31 0000059478 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:OtherDebtSecuritiesMember 2020-03-31 0000059478 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-03-31 0000059478 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:MortgageBackedSecuritiesMember 2020-03-31 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember lly:OtherEquitySecuritiesMember 2019-12-31 0000059478 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:OtherDebtSecuritiesMember 2019-12-31 0000059478 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember lly:OtherEquitySecuritiesMember 2019-12-31 0000059478 us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember us-gaap:AssetBackedSecuritiesMember 2019-12-31 0000059478 us-gaap:PensionPlansDefinedBenefitMember 2020-01-01 2020-03-31 0000059478 us-gaap:PensionPlansDefinedBenefitMember 2019-01-01 2019-03-31 0000059478 us-gaap:SubsequentEventMember 2020-04-01 2020-04-30 0000059478 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2020-01-01 2020-03-31 0000059478 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2019-01-01 2019-03-31 0000059478 lly:JapaneseAdministrativeProceedingsMember 2020-03-31 0000059478 lly:EmployeeLitigationMember country:BR 2014-05-01 2014-05-31 0000059478 lly:EmgalityPatentLitigationMember 2020-02-29 0000059478 lly:DrReddysLabMember 2018-06-01 2018-06-30 0000059478 lly:InsulinPricingLitigationAndProceedingsHouseOfRepresentativesCommitteeOnEnergyAndCommerceMember 2020-03-31 0000059478 lly:EmployeeLitigationMember country:BR 2019-07-01 2019-07-31 0000059478 lly:EmployeeLitigationMember country:BR 2018-07-01 2018-07-31 0000059478 lly:EmgalityPatentLitigationMember srt:ScenarioForecastMember 2020-04-01 2020-06-30 0000059478 lly:EmgalityPatentLitigationMember 2020-02-01 2020-02-19 0000059478 lly:EmployeeLitigationMember country:BR 2020-03-31 2020-03-31 0000059478 lly:EmployeeLitigationMember country:BR 2020-01-01 2020-03-31 0000059478 lly:DrReddysLabMember 2020-03-31 0000059478 lly:EmgalityPatentLitigationMember 2020-03-31 0000059478 lly:DrReddysLabMember 2019-12-01 2019-12-31 0000059478 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2019-01-01 2019-03-31 0000059478 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2020-01-01 2020-03-31 0000059478 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2019-01-01 2019-03-31 0000059478 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2019-01-01 2019-03-31 0000059478 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember 2020-01-01 2020-03-31 0000059478 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember 2019-01-01 2019-03-31 0000059478 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2020-01-01 2020-03-31 0000059478 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2020-01-01 2020-03-31 0000059478 us-gaap:AociAttributableToNoncontrollingInterestMember 2018-12-31 0000059478 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember lly:AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember 2020-01-01 2020-03-31 0000059478 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2019-01-01 2019-03-31 0000059478 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2019-01-01 2019-03-31 0000059478 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0000059478 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember 2019-01-01 2019-03-31 0000059478 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2020-01-01 2020-03-31 0000059478 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember 2020-01-01 2020-03-31 0000059478 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0000059478 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember lly:AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember 2019-01-01 2019-03-31 0000059478 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2020-01-01 2020-03-31 0000059478 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentContinuingOperationsMember 2019-01-01 2019-03-31 0000059478 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentContinuingOperationsMember 2019-01-01 2019-03-31 0000059478 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentContinuingOperationsMember 2019-01-01 2019-03-31 0000059478 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentContinuingOperationsMember 2018-12-31 0000059478 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentDiscontinuedOperationsMember 2018-12-31 0000059478 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentContinuingOperationsMember 2019-01-01 2019-03-31 0000059478 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentContinuingOperationsMember 2019-03-31 0000059478 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentDiscontinuedOperationsMember 2019-01-01 2019-03-31 0000059478 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentDiscontinuedOperationsMember 2019-03-31 0000059478 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2018-12-31 0000059478 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentContinuingOperationsMember 2018-12-31 0000059478 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentContinuingOperationsMember 2018-12-31 0000059478 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentContinuingOperationsMember 2018-12-31 0000059478 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentContinuingOperationsMember 2019-03-31 0000059478 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2019-03-31 0000059478 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentContinuingOperationsMember 2019-03-31 0000059478 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentContinuingOperationsMember 2019-03-31 0000059478 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentDiscontinuedOperationsMember 2020-01-01 2020-03-31 0000059478 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentContinuingOperationsMember 2020-01-01 2020-03-31 0000059478 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentContinuingOperationsMember 2019-12-31 0000059478 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentContinuingOperationsMember 2020-01-01 2020-03-31 0000059478 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentContinuingOperationsMember 2020-03-31 0000059478 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentContinuingOperationsMember 2020-01-01 2020-03-31 0000059478 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentContinuingOperationsMember 2020-01-01 2020-03-31 0000059478 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentContinuingOperationsMember 2019-12-31 0000059478 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentContinuingOperationsMember 2019-12-31 0000059478 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentContinuingOperationsMember 2020-03-31 0000059478 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentContinuingOperationsMember 2019-12-31 0000059478 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2020-03-31 0000059478 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentDiscontinuedOperationsMember 2019-12-31 0000059478 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2019-12-31 0000059478 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentContinuingOperationsMember 2020-03-31 0000059478 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentDiscontinuedOperationsMember 2020-03-31 0000059478 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember us-gaap:SegmentContinuingOperationsMember 2020-03-31 iso4217:EUR iso4217:GBP iso4217:USD xbrli:pure xbrli:shares iso4217:JPY iso4217:USD xbrli:shares iso4217:BRL lly:case lly:request lly:patent lly:lawsuit lly:demand


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
Quarterly Report Under Section 13 or 15(d) of the
Securities Exchange Act of 1934
For the quarterly period ended March 31, 2020
COMMISSION FILE NUMBER 001-6351
ELI LILLY AND COMPANY
(Exact name of Registrant as specified in its charter)
Indiana
 
35-0470950
(State or other jurisdiction of
 
(I.R.S. Employer
incorporation or organization)
 
Identification No.)
Lilly Corporate Center, Indianapolis, Indiana 46285
(Address of principal executive offices)
Registrant’s telephone number, including area code (317276-2000
Securities registered pursuant to Section 12(b) of the Exchange Act:
Title of Each Class
Trading Symbol
Name of Each Exchange On Which Registered
Common Stock (no par value)
LLY
New York Stock Exchange
1.000% Notes due 2022
LLY22
New York Stock Exchange
7 1/8% Notes due 2025
LLY25
New York Stock Exchange
1.625% Notes due 2026
LLY26
New York Stock Exchange
2.125% Notes due 2030
LLY30
New York Stock Exchange
0.625% Notes due 2031
LLY31
New York Stock Exchange
6.77% Notes due 2036
LLY36
New York Stock Exchange
1.700% Notes due 2049
LLY49A
New York Stock Exchange
Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.
Yes No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
Yes No
Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of a “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
 
 
 
  
Accelerated filer
Non-accelerated filer
 
  
Smaller reporting company
 
  
 
 
 
 
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes No
The number of shares of common stock outstanding as of April 27, 2020:
Class
 
Number of Shares Outstanding
Common
 
956,450,448

 




Eli Lilly and Company
Form 10-Q
For the Quarter Ended March 31, 2020
Table of Contents
 
 
 
 
Page
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

2



Forward-Looking Statements
This Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, and can generally be identified by the use of words such as “may,” “believe,” “will,” “expect,” “project,” “estimate,” “intend,” “anticipate,” “plan,” “continue,” or similar expressions.
In particular, information appearing under “Management's Discussion and Analysis of Results of Operations and Financial Condition” includes forward-looking statements. Forward-looking statements inherently involve many risks and uncertainties that could cause actual results to differ materially from those projected in these statements. Where, in any forward-looking statement, we (Lilly or the Company) express an expectation or belief as to future results or events, it is based on management's current plans and expectations, expressed in good faith and believed to have a reasonable basis. However, we can give no assurance that any such expectation or belief will result or will be achieved or accomplished. The following include some but not all of the factors that could cause actual results or events to differ materially from those anticipated:
uncertainties in the pharmaceutical research and development process, including with respect to the timing of anticipated regulatory approvals and launches of new products;
market uptake of recently launched products;
competitive developments affecting current products and our pipeline;
the expiration of intellectual property protection for certain of our products;
our ability to protect and enforce patents and other intellectual property;
the impact of actions of governmental and private payers affecting pricing of, reimbursement for, and access to pharmaceuticals;
regulatory compliance problems or government investigations;
regulatory actions regarding currently marketed products;
unexpected safety or efficacy concerns associated with our products;
issues with product supply stemming from manufacturing difficulties or disruptions;
regulatory changes or other developments;
changes in patent law or regulations related to data-package exclusivity;
litigation, investigations, or other similar proceedings involving past, current, or future products or commercial activities as we are largely self-insured;
unauthorized disclosure, misappropriation, or compromise of trade secrets or other confidential data stored in our information systems, networks, and facilities, or those of third parties with whom we share our data;
changes in tax law, including the impact of United States tax reform legislation enacted in December 2017 and related guidance, or events that differ from our assumptions related to tax positions;
changes in foreign currency exchange rates, interest rates, and inflation;
asset impairments and restructuring charges;
changes in accounting and reporting standards promulgated by the Financial Accounting Standards Board and the Securities and Exchange Commission (SEC);
acquisitions and business development transactions and related integration costs;
information technology system inadequacies or operating failures;
the impact of the evolving COVID-19 pandemic and the global response thereto;
reliance on third-party relationships and outsourcing arrangements; and
the impact of global macroeconomic conditions.
More information on factors that could cause actual results or events to differ materially from those anticipated is included from time to time in our reports filed with the SEC, including in Part II, Item 1A of this Form 10-Q and in our Annual Report on Form 10-K for the year ended December 31, 2019, particularly under the caption “Risk Factors”.
All forward-looking statements speak only as of the date of this report and are expressly qualified in their entirety by the cautionary statements included in or incorporated by reference into this report. Except as is required by law, we expressly disclaim any obligation to publicly release any revisions to forward-looking statements to reflect events after the date of this report.

3



PART I. Financial Information
Item 1. Financial Statements
Consolidated Condensed Statements of Operations
(Unaudited)
ELI LILLY AND COMPANY AND SUBSIDIARIES
(Dollars and shares in millions, except per-share data)
 
 
Three Months Ended
March 31,
 
2020
 
2019
Revenue (Note 2)
$
5,859.8

 
$
5,092.2

Costs, expenses, and other:
 
 
 
Cost of sales
1,215.1

 
1,138.7

Research and development
1,392.1

 
1,230.5

Marketing, selling, and administrative
1,549.6

 
1,517.1

Acquired in-process research and development (Note 3)
52.3

 
136.9

Asset impairment, restructuring, and other special charges (Note 6)
59.9

 
423.9

Other–net, (income) expense (Note 12)
(89.1
)
 
(86.0
)
 
4,179.9


4,361.1

Income before income taxes
1,679.9


731.1

Income taxes (Note 8)
223.4

 
170.0

Net income from continuing operations
1,456.5

 
561.1

Net income from discontinued operations (Note 5)

 
3,680.5

Net income
$
1,456.5


$
4,241.6

 
 
 
 
Earnings per share:
 
 
 
Earnings from continuing operations - basic
$
1.60

 
$
0.57

Earnings from discontinued operations - basic

 
3.76

Earnings per share - basic
$
1.60

 
$
4.33

 
 
 
 
Earnings from continuing operations - diluted
$
1.60

 
$
0.57

Earnings from discontinued operations - diluted

 
3.74

Earnings per share - diluted
$
1.60

 
$
4.31

 
 
 
 
Shares used in calculation of earnings per share:
 
 
 
Basic
908.2

 
979.9

Diluted
911.7

 
984.0

See notes to consolidated condensed financial statements.

4



Consolidated Condensed Statements of Comprehensive Income (Loss)
(Unaudited)
ELI LILLY AND COMPANY AND SUBSIDIARIES
(Dollars in millions)
 
 
Three Months Ended
March 31,
 
2020
 
2019
Net income
$
1,456.5

 
$
4,241.6

Other comprehensive loss from continuing operations, net of tax (Note 11)
(362.3
)
 
(4.1
)
Other comprehensive income from discontinued operations, net of tax (Note 11)

 
56.8

Other comprehensive income (loss), net of tax (Note 11)
(362.3
)
 
52.7

Comprehensive income
$
1,094.2


$
4,294.3


See notes to consolidated condensed financial statements.


5



Consolidated Condensed Balance Sheets
ELI LILLY AND COMPANY AND SUBSIDIARIES
(Dollars in millions)

 
March 31, 2020
 
December 31, 2019
Assets
(Unaudited)
 
 
Current Assets
 
 
 
Cash and cash equivalents (Note 7)
$
1,699.0

 
$
2,337.5

Short-term investments (Note 7)
78.4

 
101.0

Accounts receivable, net of allowances of $23.7 (2020) and $22.4 (2019)
5,106.1

 
4,547.3

Other receivables
1,246.4

 
994.2

Inventories
3,102.4

 
3,190.7

Prepaid expenses and other
2,761.9

 
2,538.9

Total current assets
13,994.2

 
13,709.6

Investments (Note 7)
2,148.7

 
1,962.4

Goodwill
3,779.1

 
3,679.4

Other intangibles, net
7,766.7

 
6,618.0

Deferred tax assets
2,471.6

 
2,572.6

Property and equipment, net of accumulated depreciation of $9,141.5 (2020) and $9,161.6 (2019)
7,897.9

 
7,872.9

Other noncurrent assets
3,044.6

 
2,871.2

Total assets
$
41,102.8


$
39,286.1

Liabilities and Equity
 
 
 
Current Liabilities
 
 
 
Short-term borrowings and current maturities of long-term debt
$
3,248.0

 
$
1,499.3

Accounts payable
1,207.7

 
1,405.3

Employee compensation
565.8

 
915.5

Sales rebates and discounts
4,703.9

 
4,933.6

Dividends payable

 
671.5

Income taxes payable
667.4

 
160.6

Other current liabilities
2,217.4

 
2,189.4

Total current liabilities
12,610.2

 
11,775.2

Other Liabilities
 
 
 
Long-term debt
13,982.3

 
13,817.9

Accrued retirement benefits (Note 9)
3,632.0

 
3,698.2

Long-term income taxes payable
3,621.9

 
3,607.2

Deferred tax liabilities
2,186.2

 
2,187.5

Other noncurrent liabilities
1,873.0

 
1,501.0

Total other liabilities
25,295.4

 
24,811.8

Commitments and Contingencies (Note 10)

 

Eli Lilly and Company Shareholders’ Equity
 
 
 
Common stock
598.1

 
598.8

Additional paid-in capital
6,556.1

 
6,685.3

Retained earnings
5,879.4

 
4,920.4

Employee benefit trust
(3,013.2
)
 
(3,013.2
)
Accumulated other comprehensive loss (Note 11)
(6,885.9
)
 
(6,523.6
)
Cost of common stock in treasury
(55.7
)
 
(60.8
)
Total Eli Lilly and Company shareholders’ equity
3,078.8

 
2,606.9

Noncontrolling interests
118.4

 
92.2

Total equity
3,197.2

 
2,699.1

Total liabilities and equity
$
41,102.8

 
$
39,286.1

See notes to consolidated condensed financial statements.

6



Consolidated Condensed Statements of Equity
(Unaudited)
ELI LILLY AND COMPANY AND SUBSIDIARIES

 
Equity of Eli Lilly and Company Shareholders
 
 

(Dollars in millions and shares in thousands)
Common Stock
 
Additional
Paid-in
Capital
 
Retained
Earnings
 
Employee Benefit Trust
 
Accumulated Other Comprehensive Loss
 
Common Stock in Treasury
 
Noncontrolling Interests
Shares
 
Amount
Shares
 
Amount
Balance at January 1, 2019
1,057,639

 
$
661.0

 
$
6,583.6

 
$
11,395.9

 
$
(3,013.2
)
 
$
(5,729.2
)
 
604

 
$
(69.4
)
 
$
1,080.4

Net income


 


 


 
4,241.6

 


 


 


 


 
22.2

Other comprehensive income, net of tax


 


 


 


 


 
41.7

 


 


 
11.0

Retirement of treasury shares
(89,197
)
 
(55.7
)
 


 
(10,771.8
)
 


 


 
(89,197
)
 
10,827.5

 


Purchase of treasury shares


 


 
(700.0
)
 


 


 


 
24,196

 
(2,800.0
)
 


Issuance of stock under employee stock plans, net
2,921

 
1.8

 
(202.8
)
 


 


 


 
(63
)
 
7.3

 


Stock-based compensation


 


 
75.8

 


 


 


 


 


 


Acquisition of common stock in exchange offer


 


 


 


 


 


 
65,001

 
(8,027.5
)
 


Deconsolidation of Elanco


 


 


 


 


 


 


 


 
(1,028.9
)
Other


 


 


 
13.7

 


 


 


 


 


Balance at March 31, 2019
971,363

 
$
607.1

 
$
5,756.6

 
$
4,879.4

 
$
(3,013.2
)
 
$
(5,687.5
)
 
541

 
$
(62.1
)
 
$
84.7

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Balance at January 1, 2020
958,056

 
$
598.8

 
$
6,685.3

 
$
4,920.4

 
$
(3,013.2
)
 
$
(6,523.6
)
 
530

 
$
(60.8
)
 
$
92.2

Net income


 


 


 
1,456.5

 


 


 


 


 
26.2

Other comprehensive loss, net of tax


 


 


 


 


 
(362.3
)
 


 


 


Retirement of treasury shares
(3,627
)
 
(2.3
)
 


 
(497.7
)
 


 


 
(3,627
)
 
500.0

 


Purchase of treasury shares (1)


 


 


 


 


 


 
3,627

 
(500.0
)
 


Issuance of stock under employee stock plans, net
2,500

 
1.6

 
(201.0
)
 


 


 


 
(43
)
 
5.1

 


Stock-based compensation


 


 
71.8

 


 


 


 


 


 


Other


 


 


 
0.2

 


 


 


 


 


Balance at March 31, 2020
956,929

 
$
598.1

 
$
6,556.1

 
$
5,879.4

 
$
(3,013.2
)
 
$
(6,885.9
)
 
487

 
$
(55.7
)
 
$
118.4

(1) As of March 31, 2020, there was $1.00 billion remaining under our $8.00 billion share repurchase program authorized in June 2018.
See notes to consolidated condensed financial statements.



7



Consolidated Condensed Statements of Cash Flows
(Unaudited)
ELI LILLY AND COMPANY AND SUBSIDIARIES
(Dollars in millions)
 
 
Three Months Ended
March 31,
 
2020
 
2019
Cash Flows from Operating Activities
 
Net income
$
1,456.5

 
$
4,241.6

Adjustments to Reconcile Net Income to Cash Flows from Operating Activities:
 
 
 
Gain related to disposition of Elanco (Note 5)

 
(3,680.5
)
Depreciation and amortization
273.6

 
356.5

Change in deferred income taxes
11.2

 
(72.4
)
Stock-based compensation expense
71.8

 
75.8

Acquired in-process research and development (Note 3)
52.3

 
136.9

Other changes in operating assets and liabilities, net of acquisitions and divestitures
(1,408.1
)
 
(714.3
)
Other non-cash operating activities, net
(74.9
)
 
(32.3
)
Net Cash Provided by Operating Activities
382.4

 
311.3

Cash Flows from Investing Activities
 
 
 
Net purchases of property and equipment
(258.3
)
 
(203.7
)
Proceeds from sales and maturities of short-term investments
36.8

 
35.9

Purchases of short-term investments

 
(33.7
)
Proceeds from sales of noncurrent investments
54.5

 
83.6

Purchases of noncurrent investments
(83.0
)
 
(60.6
)
Cash paid for acquisitions, net of cash acquired (Note 3)
(849.3
)
 
(6,917.7
)
Purchases of in-process research and development
(13.0
)
 
(196.9
)
Other investing activities, net
51.4

 
(385.6
)
Net Cash Used for Investing Activities
(1,060.9
)
 
(7,678.7
)
Cash Flows from Financing Activities
 
 
 
Dividends paid
(671.3
)
 
(637.2
)
Net change in short-term borrowings
1,748.7

 
1,850.4

Proceeds from issuance of long-term debt

 
4,448.3

Repayments of long-term debt
(276.3
)
 
(600.0
)
Purchases of common stock
(500.0
)
 
(3,500.0
)
Other financing activities, net
(194.4
)
 
(193.7
)
Net Cash Provided by Financing Activities
106.7

 
1,367.8

Effect of exchange rate changes on cash and cash equivalents
(66.7
)
 
37.8

 
 
 
 
Net decrease in cash and cash equivalents
(638.5
)
 
(5,961.8
)
Cash and cash equivalents at January 1 (2019 includes $677.5 of discontinued operations)
2,337.5

 
7,998.2

Cash and Cash Equivalents at March 31
$
1,699.0

 
$
2,036.4

See notes to consolidated condensed financial statements.



8



Notes to Consolidated Condensed Financial Statements
(Tables present dollars in millions, except per-share data)
Note 1: Basis of Presentation
We have prepared the accompanying unaudited consolidated condensed financial statements in accordance with the requirements of Form 10-Q and, therefore, they do not include all information and footnotes necessary for a fair presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States (GAAP). In our opinion, the financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for a fair presentation of the results of operations for the periods shown. In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates.
The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2019. We issue our financial statements by filing them with the Securities and Exchange Commission and have evaluated subsequent events up to the time of the filing of our Form 10-Q.
All per-share amounts, unless otherwise noted in the footnotes, are presented on a diluted basis, that is, based on the weighted-average number of outstanding common shares plus the effect of incremental shares from our stock-based compensation programs.
We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide. A global research and development organization and a supply chain organization are responsible for the discovery, development, manufacturing, and supply of our products. Regional commercial organizations market, distribute, and sell the products. The business is also supported by global corporate staff functions. Our determination that we operate as a single segment is consistent with the financial information regularly reviewed by the chief operating decision maker for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting for future periods.



9



Note 2: Revenue
The following table summarizes our revenue recognized in our consolidated condensed statements of operations:
 
Three Months Ended
March 31,
 
2020
 
2019
Net product revenue
$
5,403.5

 
$
4,692.3

Collaboration and other revenue (1)
456.3

 
399.9

Revenue
$
5,859.8

 
$
5,092.2

(1) Collaboration and other revenue associated with prior period transfers of intellectual property was $35.4 million and $35.5 million during the three months ended March 31, 2020 and 2019, respectively.
We recognize revenue primarily from two different types of contracts, product sales to customers (net product revenue) and collaborations and other arrangements. Revenue recognized from collaborations and other arrangements includes our share of profits from the collaboration, as well as royalties, upfront and milestone payments we receive under these types of contracts. See Note 4 for additional information related to certain of our collaborations and other arrangements. Collaboration and other revenue disclosed above includes the revenue from the Trajenta® and Jardiance® families of products resulting from our collaboration with Boehringer Ingelheim discussed in Note 4. Substantially all of the remainder of collaboration and other revenue is related to contracts accounted for as contracts with customers.
Adjustments to Revenue
Adjustments to revenue recognized as a result of changes in estimates for our most significant U.S. sales returns, rebates, and discounts liability balances for products shipped in previous periods were approximately 2 percent and 3 percent of U.S. revenue during the three months ended March 31, 2020 and 2019, respectively.
Contract Liabilities
Our contract liabilities result from arrangements where we have received payment in advance of performance under the contract and do not include sales returns, rebates, and discounts. Changes in contract liabilities are generally due to either receipt of additional advance payments or our performance under the contract.
The following table summarizes contract liability balances:
 
March 31, 2020
 
December 31, 2019
Contract liabilities
$
307.8

 
$
264.6


During the three months ended March 31, 2020 and 2019, revenue recognized from contract liabilities as of the beginning of the year was not material. Revenue expected to be recognized in the future from contract liabilities as the related performance obligations are satisfied is not expected to be material in any one year.


10



Disaggregation of Revenue
The following table summarizes revenue by product:
 
Three Months Ended
March 31,
 
2020
 
2019
 
United States (U.S.) (1)
Outside U.S.
Total
 
U.S. (1)
Outside U.S.
Total
Revenue—to unaffiliated customers:
 
 
 
 
 
 
 
Diabetes:
 
 
 
 
 
 
 
Trulicity®
$
929.5

$
299.9

$
1,229.4

 
$
665.6

$
214.1

$
879.7

Humalog® (2)
398.6

297.2

695.8

 
448.6

282.2

730.8

Humulin®
214.1

101.5

315.7

 
201.3

96.4

297.7

Basaglar®
230.4

73.3

303.7

 
198.2

53.2

251.4

Jardiance (3)
144.6

122.9

267.5

 
125.2

78.4

203.6

Trajenta (4)
28.7

64.5

93.2

 
47.4

84.6

131.9

Other Diabetes
45.3

18.4

63.6

 
33.1

24.7

57.9

Total Diabetes
1,991.2

977.7

2,968.9

 
1,719.4

833.6

2,553.0

 
 
 
 
 
 
 
 
Oncology:
 
 
 
 
 
 
 
Alimta®
324.2

235.8

560.1

 
281.8

217.4

499.2

Cyramza®
89.1

149.9

239.0

 
75.1

123.2

198.3

Verzenio®
129.4

58.6

188.0

 
93.5

15.9

109.4

Erbitux®
117.8

13.0

130.8

 
113.3

5.1

118.4

Other Oncology
(2.6
)
86.3

83.6

 
30.2

57.3

87.4

Total Oncology
657.9

543.6

1,201.5

 
593.9

418.9

1,012.7

 
 
 
 
 
 
 
 
Immunology:
 
 
 
 
 
 
 
Taltz®
327.5

116.0

443.5

 
180.8

71.7

252.5

Olumiant®
11.3

128.4

139.7

 
6.4

75.7

82.1

Other Immunology
2.6


2.6

 



Total Immunology
341.4

244.4

585.8

 
187.2

147.4

334.7

 
 
 
 
 
 
 
 
Neuroscience:
 
 
 
 
 
 
 
Cymbalta®
11.6

198.8

210.4

 
10.3

153.8

164.1

Zyprexa®
11.2

87.2

98.4

 
9.3

97.9

107.2

Emgality®
67.3

6.7

74.0

 
12.2

2.1

14.2

Other Neuroscience
20.2

60.5

80.7

 
19.3

88.2

107.6

Total Neuroscience
110.3

353.2

463.5

 
51.1

342.0

393.1

 
 
 
 
 
 
 
 
Other:
 
 
 
 
 
 
 
Forteo®
122.5

149.8

272.4

 
125.9

187.0

312.9

Cialis®
26.1

167.0

193.0

 
143.2

164.9

308.2